Evidence map›Paper›PMID 25961923›Full record

ArticleOncogene2016

MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response.

F Mancini, L Pieroni, V Monteleone, R Lucà, L Fici, E Luca, A Urbani, S Xiong, S Soddu, R Masetti and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. The long and the short of it: the MDM4 tail so far.Journal of molecular cell biology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

F ManciniInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
L PieroniProteomic and Metabolomic Laboratory, Fondazione Santa Lucia, Roma, Italy.
V MonteleoneInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
R LucàInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
L FiciInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
E LucaInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
A UrbaniProteomic and Metabolomic Laboratory, Fondazione Santa Lucia, Roma, Italy.
S XiongDepartment of Genetics, M.D. Anderson Cancer Center, Houston, TX, USA.
S SodduRegina Elena National Cancer Institute, Roma, Italy.
R MasettiDepartment of Obstetrics and Gynaecology, Catholic University of Roma, Roma, Italy.
G LozanoDepartment of Genetics, M.D. Anderson Cancer Center, Houston, TX, USA.
A PontecorviDepartment of Endocrinology and Metabolism, Catholic University of Roma, Roma, Italy.
F MorettiInstitute of Cell Biology and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
National Research Council · ITFondazione Santa Lucia · ITThe University of Texas MD Anderson Cancer Center · USUniversità Cattolica del Sacro Cuore · ITInstitute of Cell Biology and Neurobiology · IT

Funding

PATHWAY OF TUMOR SUPPRESSIONR01CA047296 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GUILLERMINA LOZANO · 1993 to 2026
$8.0M
NCI NIH HHS R01 CA047296
6 · The paper itself

Abstract

The p53 inhibitor, MDM4 (MDMX) is a cytoplasmic protein with p53-activating function under DNA damage conditions. Particularly, MDM4 promotes phosphorylation of p53 at Ser46, a modification that precedes different p53 activities. We investigated the mechanism by which MDM4 promotes this p53 modification and its consequences in untransformed mammary epithelial cells and tissues. In response to severe DNA damage, MDM4 stimulates p53Ser46(P) by binding and stabilizing serine-threonine kinase HIPK2. Under these conditions, the p53-inhibitory complex, MDM4/MDM2, dissociates and this allows MDM4 to promote p53/HIPK2 functional interaction. Comparative proteomic analysis of DNA damage-treated cells versus -untreated cells evidenced a diffuse downregulation of proteins with anti-apoptotic activity, some of which were targets of p53Ser46(P)/HIPK2 repressive activity. Importantly, MDM4 depletion abolishes the downregulation of these proteins indicating the requirement of MDM4 to promote p53-mediated transcriptional repression. Consistently, MDM4-mediated HIPK2/p53 activation precedes HIPK2/p53 nuclear translocation and activity. Noteworthy, repression of these proteins was evident also in mammary glands of mice subjected to γ-irradiation and was significantly enhanced in transgenic mice overexpressing MDM4. This study evidences the flexibility of MDM2/MDM4 heterodimer, which allows the development of a positive activity of cytoplasmic MDM4 towards p53-mediated transcriptional function. Noteworthy, this activity uncovers coordinated repression of molecules with shared anti-apoptotic function which precedes active cell apoptosis and that are frequently overexpressed and/or markers of tumour phenotype in human cancer.

Indexed as

AnimalsApoptosisBase SequenceCarrier ProteinsCell Cycle ProteinsCytoplasmDNA DamageEpithelial CellsFemaleFibroblastsHCT116 CellsHumansMice, Inbred C57BLMice, TransgenicMolecular Sequence DataNuclear ProteinsCarrier ProteinsCell Cycle ProteinsHIPK2 protein, humanMDM4 protein, humanMdm4 protein, mouseNuclear ProteinsProtein Serine-Threonine KinasesProto-Oncogene ProteinsSerineTumor Suppressor Protein p53Ubiquitin-Protein Ligases

Identifiers

PMID25961923
PMCPMC4717155
OpenAlexW1553632181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.